ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ANIP
CUSIPN/A
Phone218-634-3500
Debt
Debt-to-Equity Ratio1.11
Current Ratio3.62
Quick Ratio2.75
Price-To-Earnings
Trailing P/E Ratio18.86
Forward P/E Ratio12.54
P/E GrowthN/A
Sales & Book Value
Annual Sales$176.84 million
Price / Sales4.54
Cash Flow$6.0248 per share
Price / Cash11.30
Book Value$14.99 per share
Price / Book4.54
Profitability
EPS (Most Recent Fiscal Year)$3.61
Net Income$-1,070,000.00
Net Margins0.01%
Return on Equity27.16%
Return on Assets12.43%
Miscellaneous
Employees173
Outstanding Shares11,800,000
ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) Frequently Asked Questions
What is ANI Pharmaceuticals Inc Common Stock's stock symbol?
ANI Pharmaceuticals Inc Common Stock trades on the NASDAQ under the ticker symbol "ANIP."
How were ANI Pharmaceuticals Inc Common Stock's earnings last quarter?
ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) posted its quarterly earnings data on Tuesday, May, 8th. The specialty pharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.04. The specialty pharmaceutical company had revenue of $46.48 million for the quarter, compared to analysts' expectations of $49.93 million. ANI Pharmaceuticals Inc Common Stock had a return on equity of 27.16% and a net margin of 0.01%. The business's revenue was up 26.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.74 earnings per share. View ANI Pharmaceuticals Inc Common Stock's Earnings History.
What guidance has ANI Pharmaceuticals Inc Common Stock issued on next quarter's earnings?
ANI Pharmaceuticals Inc Common Stock updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share guidance of $5.43-6.08 for the period, compared to the Thomson Reuters consensus estimate of $5.55. The company issued revenue guidance of $212-228 million, compared to the consensus revenue estimate of $215.67 million.
What price target have analysts set for ANIP?
3 Wall Street analysts have issued twelve-month target prices for ANI Pharmaceuticals Inc Common Stock's shares. Their predictions range from $80.00 to $85.00. On average, they anticipate ANI Pharmaceuticals Inc Common Stock's stock price to reach $82.3333 in the next twelve months. View Analyst Ratings for ANI Pharmaceuticals Inc Common Stock.
What are Wall Street analysts saying about ANI Pharmaceuticals Inc Common Stock stock?
Here are some recent quotes from research analysts about ANI Pharmaceuticals Inc Common Stock stock:
- 1. According to Zacks Investment Research, "ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. " (5/14/2018)
- 2. Canaccord Genuity analysts commented, "We remain pessimistic about the company’s ability to execute a successful clinical trial required for FDA approval. The planned 2018 $10M cost-cutting initiative suggests to us that Eagle isn’t too confident either (and is generally in line with our expectations). Eagle’s other pipeline programs like fulvestrant and drug-induced hyperthermia are questionable and may require a few more years of development under a best case scenario, in our view. There was strangely no mention of the Alimta RTD PDUFA in October. Eagle also reiterated prior 2017 expense guidance of $50-$53M in SG&A (excluding stock based comp) and $26- $30M R&D (excluding stock-based comp). We note the company was previously reporting GAAP earnings so the change is slightly new. We also note that Eagle has expanded its borrowing capacity by $100M (suggesting to us that it may want to bring in new assets) but simultaneously announced an additional $100M buyback program." (8/9/2017)
Who are some of ANI Pharmaceuticals Inc Common Stock's key competitors?
Some companies that are related to ANI Pharmaceuticals Inc Common Stock include Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Supernus Pharmaceuticals (SUPN), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), Portola Pharmaceuticals (PTLA), The Medicines (MDCO), Emergent Biosolutions (EBS), Evotec (EVTCY), TESARO (TSRO), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT) and Clovis Oncology (CLVS).
Who are ANI Pharmaceuticals Inc Common Stock's key executives?
ANI Pharmaceuticals Inc Common Stock's management team includes the folowing people:
- Mr. Arthur S. Przybyl, CEO, Pres & Director (Age 61)
- Mr. Stephen P. Carey, CFO & VP of Fin. (Age 47)
- Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 55)
- Mr. Robert W. Schrepfer, Sr. VP of Bus. Devel. & Specialty Sales (Age 46)
- Dr. David J. Sullivan, VP of Quality Operations
Has ANI Pharmaceuticals Inc Common Stock been receiving favorable news coverage?
News stories about ANIP stock have trended somewhat positive recently, Accern reports. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ANI Pharmaceuticals Inc Common Stock earned a media sentiment score of 0.13 on Accern's scale. They also gave news coverage about the specialty pharmaceutical company an impact score of 47.24 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are ANI Pharmaceuticals Inc Common Stock's major shareholders?
ANI Pharmaceuticals Inc Common Stock's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.05%), Dimensional Fund Advisors LP (3.99%), LSV Asset Management (2.61%), Northern Trust Corp (0.96%), Allianz Asset Management GmbH (0.71%) and Allianz Asset Management GmbH (0.72%). Company insiders that own ANI Pharmaceuticals Inc Common Stock stock include Arthur Przybyl, Daniel Raynor, James G Marken, Robert W Schrepfer and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals Inc Common Stock.
Which major investors are selling ANI Pharmaceuticals Inc Common Stock stock?
ANIP stock was sold by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Allianz Asset Management GmbH, Allianz Asset Management GmbH, ETRADE Capital Management LLC, Chicago Equity Partners LLC, Dynamic Technology Lab Private Ltd, Schwab Charles Investment Management Inc. and Northern Trust Corp. Company insiders that have sold ANI Pharmaceuticals Inc Common Stock company stock in the last year include Arthur Przybyl, Daniel Raynor, James G Marken, Robert W Schrepfer and Tracy Marshbanks. View Insider Buying and Selling for ANI Pharmaceuticals Inc Common Stock.
Which major investors are buying ANI Pharmaceuticals Inc Common Stock stock?
How do I buy shares of ANI Pharmaceuticals Inc Common Stock?
Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ANI Pharmaceuticals Inc Common Stock's stock price today?
One share of ANIP stock can currently be purchased for approximately $68.08.
How big of a company is ANI Pharmaceuticals Inc Common Stock?
ANI Pharmaceuticals Inc Common Stock has a market capitalization of $797.17 million and generates $176.84 million in revenue each year. The specialty pharmaceutical company earns $-1,070,000.00 in net income (profit) each year or $3.61 on an earnings per share basis. ANI Pharmaceuticals Inc Common Stock employs 173 workers across the globe.
How can I contact ANI Pharmaceuticals Inc Common Stock?
ANI Pharmaceuticals Inc Common Stock's mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]
MarketBeat Community Rating for ANI Pharmaceuticals Inc Common Stock (ANIP)
MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals Inc Common Stock and other stocks. Vote "Outperform" if you believe ANIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
